FibroScint (Tc-99m F4A)
Detection of thrombus in patients with Left Ventricular Assist Devices (LVADs)
Pre-clinicalActive
Key Facts
Indication
Detection of thrombus in patients with Left Ventricular Assist Devices (LVADs)
Phase
Pre-clinical
Status
Active
Company
About Capella Imaging
Capella Imaging is a private, pre-clinical stage biotech developing targeted diagnostic imaging agents, with a primary focus on cardiovascular thrombus detection. The company's lead program, FibroScint (Tc-99m F4A), is a peptide-based radiopharmaceutical designed for SPECT imaging of fibrin, a key component of blood clots. Initial development is targeting the orphan indication of thrombus in LVAD patients, a population with significant unmet diagnostic needs and high complication rates from anticoagulation therapy. The founding team combines deep expertise in radiopharmaceutical chemistry, cardiology, and nanomedicine.
View full company profile